Please login to the form below

Not currently logged in
Email:
Password:

Three directors join UK’s MHRA

Valerie Beral, Alexander Markham and David Webb join UK regulatory body

The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has named three new non-executive directors.

Valerie Beral, MHRA

Dame Valerie Beral, Prof Sir Alexander Markham and Prof David Webb will all join the board of the MHRA, which regulates the safety of medicines and medical devices in the UK.

Dame Valerie (pictured right) is director of the cancer epidemiology unit at the University of Oxford, where her research has included reproductive, hormonal and infectious agents in cancer.

She also helped lead the Million Women Study, which helped demonstrate that hormone replacement therapy increases a woman's risk of developing breast cancer.

Prof Markham is professor of medicine at the University of Leeds and a former CEO of the charity Cancer Research UK.

He is also director of the molecular medicine unit at St James's University Hospital and chairman of the NHS Connecting for Health Research Capability Programme, in addition to serving on a number of panels of the Medical Research Council.

David Webb, MHRA

Prof Webb (pictured left) is Christison professor of therapeutics and clinical pharmacology at the University of Edinburgh.

His research has focused on internal medicine, hypertension and cardiovascular risk management, and he established Edinburgh University's Wellcome Trust cardiovascular research initiative and centre for cardiovascular science.

In addition to his academic role, he is the current leader of the Scottish Translational Medicine and Therapeutics Initiative (STMTI), established by the Wellcome Trust.

“I'm delighted that Dame Valerie, Sir Alex and Professor Webb have accepted appointments as non-executive directors of the MHRA,” said Sir Gordon Duff, chair of the MHRA.

“They will bring highly relevant experience and expertise to our board at a time of significant development of the Agency, and will contribute importantly to our strategic leadership.

30th July 2013

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics